Compare SMWB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | VTYX |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 747.7M | 713.6M |
| IPO Year | 2021 | 2021 |
| Metric | SMWB | VTYX |
|---|---|---|
| Price | $7.27 | $7.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $14.38 | ★ $14.60 |
| AVG Volume (30 Days) | 317.5K | ★ 1.4M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,429,000.00 | N/A |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $13.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.25 | N/A |
| 52 Week Low | $6.36 | $0.78 |
| 52 Week High | $17.64 | $10.55 |
| Indicator | SMWB | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 46.58 |
| Support Level | $6.97 | $8.61 |
| Resistance Level | $7.70 | $9.30 |
| Average True Range (ATR) | 0.32 | 0.64 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 49.42 | 46.94 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.